Introduction
============

Given that the prevalence of asthma may be increasing in many populations world-wide ([@B30]), it is significant that advances in treatment may result from an improved understanding of both the molecular basis of asthma and its responsiveness to therapy. Both asthma susceptibility loci, the genetic variability that confers risk for complex respiratory traits that lead to asthma, and pharmacogenetics, the genetic variability that confers responsiveness of an individual to pharmaceutical therapy, may be best modeled as independent complex traits with both genetic and environmental (GXE) contributions. Since variability in the genes encoding the proteins essential for inflammation may influence risk for many aspects of asthmatic inflammation ([@B26]), it is to be expected that it might also increase the susceptibility to asthma independent of their pharmacogenetic relevance ([@B124]). Here, we discuss the relative contribution of genes in the cysteinyl leukotriene (CysLT) pathway to both the etiology of asthma itself and a person's responsiveness to leukotriene modifying (LTM) drugs.

While in some cases the genetic variants that result in disease also encode protein targets for pharmaceutical interventions, this relationship is often not consistent even with polymorphisms of a G protein-coupled receptor (GPCR) system such as the one that mediates CysLT inflammation. For example, while variability in the genes encoding drug targets such as the cysteinyl leukotriene 1 (*CYSLTR1*) and 2 (*CYSLTR2*) receptor genes may both contribute to risk for atopic asthma in some populations ([@B122], [@B127], [@B118]; [@B89]; [@B13]; [@B134]), only the cysteinyl leukotriene 1 (CYSLTR1) receptor is targeted by LTMs. We can only speculate, however, on the role that that variability in the cysteinyl leukotriene 2 (CYSLTR2) receptor may have in LTM pharmacogenetics since drugs targeting the CYSLTR2 receptor are not widely available.

In general, respiratory disease itself, and patient response to therapy, may be best modeled as independent complex traits with both genetic and environmental contributions. The GPCR associated with asthma, the (*NPSR1*) neuropeptide S receptor 1 ([@B60]; [@B57]; [@B74]; [@B88]), may represent an exception inasmuch as it also defines a potential therapeutic target. As a result, many advances in pharmacogenetics have resulted not from linkage or candidate gene studies but from Genome Wide Association Studies (GWAS). Hence, the field of pharmacogenomics has become axiomatic in the study of patient response and non-response to medication, adverse drug reactions, and optimizing drug dose for the individual.

The study of *CYSLTR1* and *CYSLTR2* gene variability in asthma, therefore, must be considered in the context of the genetic polymorphisms found within the synthesis pathway genes as well as genes that modify patient response to LTMs. The LTMs used to treat asthma, such as montelukast, a drug which targets cysteinyl leukotriene 1 (CYSLTR1) receptor protein, have a greater than 20% non-response rate ([@B83]). While some of the pharmacogenetic determinants of LTM response are attributable to variability in genes that are integral ([@B48]; [@B81]) to the signaling of cysteinyl leukotrienes (**Figure [1](#F1){ref-type="fig"}**), many true pharmacogenetic variants are located in genes that lie directly outside the pathway ([@B23], [@B22]).

![**Cysteinyl leukotriene synthesis pathway.** Leukotriene biosynthesis inhibitors act on either 5-lipoxygenase or its activating protein (FLAP). The class of cysteinyl leukotriene (CysLT) receptor antagonists target the CysLT receptors CYSLTR1 and CYSLTR2. 5-HPETE, 5-hydroxyperoxy-eiocosatetraenoic acid.](fphar-07-00299-g001){#F1}

In order to undertake GWAS studies of complex traits, a large sample size is generally required. Thus, informative studies of the genetic basis of drug response are conducted among large samples of unrelated individuals recruited from a given population. This is especially true for asthma phenotypes studied in out-bred populations since they tend to be genetically heterogeneous ([@B80]; [@B77]; [@B102]; [@B31]; [@B75]). By contrast, small candidate gene studies have achieved reasonable power for detecting variants that confer risk ([@B72]). Since data from sequencing large patient cohorts has become available, it has been possible to assess the wider relevance of some observations originally made in smaller studies.

For example, our study of atopic asthma in the Tristan da Cunha isolate provided early insight into CysLT pharmacogenetics ([@B125]; [@B18]; [@B13]). In particular, the hypomorphic Met201Val CYSLTR2 variant identified on Tristan da Cunha ([@B122]) has since been associated with atopy in large out-bred populations ([@B89]). Selected examples of GPCR variants associated with asthma phenotypes are presented in **Table [1](#T1){ref-type="table"}**. **Tables [2](#T2){ref-type="table"}** and **[3](#T3){ref-type="table"}** present selected variants of the *CYSLTR1* and *CYSLTR2* genes.

###### 

Human G-protein-coupled receptor (GPCR) variants associated with asthma endophenotype or altered pharmacology.

  Receptor (gene name)                                                      Variant/allele                                                       Disease/phenotype                                  Pharmacology                                                                                                                              Reference
  ------------------------------------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  Endothelin-1 receptor type A (*EDNRA*)                                    A*fi* II                                                             Atopy; IgE levels increased                        Altered receptor expression                                                                                                               [@B71]; [@B77]
  Beta2-adrenergic receptor (*ADRB2*)                                       R16 \> G                                                             Reduced lung function; nocturnal asthma/severity   Downregulation enhanced; albuterol response decreased                                                                                     [@B37]; [@B7]
                                                                            Q27 \> E                                                             Hypertension risk; obesity; IgE levels increased   Downregulation resistant; albuterol response increased; drug hypersensitivity                                                             [@B92]; [@B24]; [@B28]
                                                                            G16/E27 haplotype                                                    Asthma, heart disease, immune disorders                                                                                                                                                      [@B28]
                                                                            C341 \> G                                                            None known                                         Uncoupling from Gs/adenylyl cyclase system                                                                                                [@B59]
  Prostaglandin D2 receptor (*PTGDR*)                                       Promoter SNPs undermine normal helper T anti-inflammatory response   Asthma                                             Altered receptor expression anti- immune response to PGD2                                                                                 [@B21]; [@B85]
  Chemoattractant receptor on Th2 cells (*CRTH2*/*GPR44*)                   3′ UTR SNPs: 1651G \> A, 1544C/1651A                                 Asthma                                             Altered receptor expression; inflammatory response to PGD2                                                                                [@B39]; [@B131]
  Thromboxane A2 receptor (*TBXA2R*)                                        TP-alpha and TP-beta isoforms SNPs                                   Asthma, atopy and aspirin-intolerant asthma                                                                                                                                                  [@B129]; [@B53]
  Cysteinyl leukotriene receptor 1 (*CYSLTR1*)                              G300S                                                                Atopy                                              Receptor activation                                                                                                                       [@B119]; [@B134]
  Cysteinyl leukotriene receptor 2 (*CYSLTR2*)                              M201V                                                                Various populations                                Receptor inactivation                                                                                                                     [@B122], [@B127]; [@B89]; [@B13]
  Prostaglandin D2 receptor (PTGDR)                                         -441T/C                                                              No disease association                             Montelukast response                                                                                                                      [@B48]
  Chemokine \[C-C motif\] receptor 5 (*CCR5*)                               32 bp deletion; 59029 A \> G                                         Risk of asthma decreased                           Diminished CCR5 expression on Th1 cells results in a preponderance of Th2 cells; decreased binding to activity; decreased binding to CC   [@B35]; [@B108]; [@B2]
  G-protein-coupled receptor associated with asthma (*GPRA* or *GPSR154*)   GPRA-B isoform over-expressed in bronchial epithelia of asthmatics   Asthma                                             Altered RANTES, MIP-1-alpha ligand suggests that GPRA is a potential drug target                                                          [@B60]; [@B57]; [@B74]; [@B88]

IgE, immunoglobulin E; MIP-1alpha, macrophage inhibitory protein; PGD2, prostaglandin D2; RANTES, regulated on activation, normal T cell expressed and secreted; SNP, single nucleotide polymorphism; UTR, untranslated region.

###### 

CYSLTR1 receptor variants: naturally occurring polymorphisms and *in vitro* engineered mutants.

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Variant, SNP or access code)   Type                 SNP access code   Disease association                                         Reference
  ------------------------------ -------------------- ----------------- ----------------------------------------------------------- -----------
  c.-945T/C\                     Promotor\            rs321029\         Associated with IgE /atopy\                                 [@B55]\
  c.-786C/A\                     Promotor\            rs2637204\        Aspirin intolerant asthma (AIA) associated\                 [@B136]\
  c.-647G/A                      Promotor             rs2806489         Not associated with IgE; Associated with atopy in females   [@B29]\
                                                                                                                                    [@B54]

  TCG (above)\                   Haplotype\           \                 Upregulating haplotype not associated\                      [@B136]\
  c.-566C/T\                     Promotor\            rs7066737\        Not associated\                                             [@B29]\
  c. 927T/C                      synonymous\          rs320995          Not associated\                                             [@B20]\
                                 \                                      Associated with asthma\                                     [@B97]\
                                 \                                      Not associated with atopic asthma\                          [@B45]\
                                 \                                      Atopy severity in females\                                  [@B4]\
                                 \                                      Not associated                                              [@B36]\
                                 Various haploblock                                                                                 [@B3]

  c.898 G/A                      C-terminus                             300Ser is a hypermorphic variant;\                          [@B119]
                                                                        Increased Ca^2+^ flux                                       

                                                                        Normal expression and desensitization\                      [@B134]
                                                                        Increased LTD4 binding;\                                    
                                                                        Increased Inositol Phosphate                                
  ---------------------------------------------------------------------------------------------------------------------------------------------

aa, amino acid; IC, intracellular loop; SNP, single nucleotide polymorphism; TM, transmebrane helix. Approximate allele frequency as reported by the Exome Aggregation Consortium (ExAC), Cambridge, MA, USA (

http://exac.broadinstitute.org

).

###### 

CYSLTR2 receptor variants: naturally occurring polymorphisms and *in vitro* engineered mutants.

  ------------------------------------------------------------------------------------------------------------------------------
  Nucleotide position       Type         SNP access code   Disease association                                       Reference
  ------------------------- ------------ ----------------- --------------------------------------------------------- -----------
  g.-1220A/C\               Promotor\    \                 Associated with asthma\                                   [@B33]\
  c.-819 T \> G\            Haplotype\   \                 Aspirin intolerant asthma\                                [@B86]\
  c.2078 C \> T\            \            \                 Stronger association with LTC4S c.-444A \> C\             [@B49]\
  c.2534A \> G\             \            \                 Not associated with atopic dermatitis\                    \
  c.3105 A/G (Exon1-UTR)\   Haplotype\   rs1323552\        Not associated\                                           [@B58]\
  c.-2534A \> G\            \            rs912278\         \                                                         \
  c.601 A/G                 Coding       rs41347648        201Ser is associated with atopic asthma\                  [@B122]\
                                                           201Ser is a hypomorphic variant; decreased Ca^2+^ flux\   \
                                                           Common allele associated with protection against atopy\   [@B125]\
                                                           Associated with atopy; Hypomorphic\                       [@B89]\
                                                           201Ser is hypomorphic\                                    [@B13]
                                                           Decreased LTD4 binding\                                   
                                                           Decreased inositol phosphate production                   

  ------------------------------------------------------------------------------------------------------------------------------

aa, amino acid; IC, intracellular loop; SNP, single nucleotide polymorphism; TM, transmebrane helix. Approximate allele frequency as reported by the Exome Aggregation Consortium (ExAC), Cambridge, MA, USA (

http://exac.broadinstitute.org

).

Population Isolates
-------------------

Studies of population isolates rely upon the fact that a founder effect limits genetic heterogeneity and results in greatly increased prevalence rates ([@B94]; [@B135]). In the Tristan da Cunha isolate, for example, there is a 45% prevalence of atopy and a 36% prevalence of asthma ([@B70]; [@B135]; [@B16]; [@B17]). By comparison, the prevalence of asthma in most out-bred populations rarely exceeds 10%. The severity of the Tristan da Cunha atopy phenotype may be reflected in events such as the Tristan da Cunha influenza epidemic of 1971 ([@B70]; [@B135]; [@B16]; [@B17]).

Analyzing the transmission of genetic markers in a large extended pedigree such as a population isolates, provides the opportunity to identify risk alleles originating from common ancestry ([@B105], [@B106]). In particular, this enrichment optimizes the analysis of complex traits for gene-gene interaction effects. Even though the asthma phenotype is relatively homogenous on Tristan da Cunha, the fact that more than one of the seven founders that populated the island after 1812 were asthmatic ([@B63]) suggests that the disorder manifested by the islanders is influenced by complex inheritance.

The Tristan da Cunha findings ([@B122], [@B119], [@B118]), therefore, must be interpreted not only in the context of a founder effect ([@B135]; [@B103]; [@B19]) but also in the context of the many genes that confer risk to asthma in out-bred populations: including GPCRs variants (**Table [1](#T1){ref-type="table"}**).

Out-Bred Populations
--------------------

Genome Wide Association Studies have confirmed that variants of the *DENND1B* gene, located on chromosome 1q31 ([@B102]) and the *ORMDL3* gene, located on chromosome 17q12 ([@B80]) underlie asthma pathogenesis in many populations ([@B31]; [@B75]). Other genes including ADAM33, CCL5, CD14, DPP10, EDN1, NPSR1, GSTP1, IL12B, IL13, IL4, IL4R, PTGDR, TNF, and VDR have also been found to be commonly associated with asthma in various study populations ([@B77]). Asthma resulting from certain genotypes has shown distinct responses to drug treatment in some instances ([@B11]). Differentiating the genetic basis of a heterogeneous disease such as asthma, therefore, creates the opportunity to tailor specific therapeutic regimens to the resulting endophenotype ([@B91]; [@B78]; [@B123], [@B120],[@B126]).

G protein-coupled receptors are the primary drug targets for drug interventions into many forms of asthma. Many advances in therapeutics have resulted from the identification of GPCR variants that are associated with disease. Polymorphisms of the β~2~-adrenergic receptor (*ADRB2*) gene may be among the most clinically relevant with respect to drug response ([@B128]). Like the subsequent study of many GPCR variants, homology with the prototypical GPCR, rhodopsin ([@B62]), was used to predict the functional significance of sequence alterations. Many of these studies were later evaluated *in vitro* ([@B91]; [@B62]).

Early studies showed that β~2~-adrenergic receptor variants with altered pharmacological response are more common in patients with asthma ([@B114], [@B115]; [@B113]; [@B37]) as well as congestive heart failure ([@B120]). More recent studies have linked polymorphisms of *ADRB2* to altered drug response ([@B7]; [@B73]). Asthma treatment with albuterol, which is targeted to ADRB2, is often associated with increased hypersensitivity ([@B92]; [@B24]; [@B64]; [@B28]; [@B43]; [@B66]). Work is currently underway to identify ADRB2 polymorphisms in populations, such as the residents of Grenada, where 30% of the children are reported to have asthma according to a modified ISAAC survey ([@B87]; [@B128]).

Other candidate gene studies have identified GPCR gene variants that are associated with asthma phenotypes from various populations. *In vivo* and *in vitro* studies have determined functional roles for many GPCR variants ([@B91]), but evaluation of their physiological role in disease remains a challenge ([@B121]). In addition to CYSLTR1 and CYSLTR2 receptor polymorphisms (**Tables [2](#T2){ref-type="table"}** and **[3](#T3){ref-type="table"}**), GPCR variants of significance to asthma pharmacogenetics are presented in **Table [1](#T1){ref-type="table"}**. These receptors include the endothelin-1 receptor type A (*EDNRA*; [@B71]; [@B77]), prostaglandin D~2~ (*PTGDR2*; [@B21]; [@B85]), thromboxane A~2~ (*TBXA2R*; [@B129]; [@B53]) and chemokine \[C-C motif\] receptor 5 (*CCR5*) receptors ([@B35]; [@B108]; [@B2]).

Leukotriene Modifier (LTM) Pharmacogenetics
===========================================

The cysteinyl leukotriene ligands (CysLT), including leukotriene C4 (LTC4), D4 (LTD4) and E4 (LTE4), are powerful bronchoconstrictors and pro-inflammatory mediators of atopic asthma ([@B96]; [@B12]). They are released by mast cells and macrophages during asthma attacks ([@B99]). The severity of an asthma attack can be influenced by the cellular concentrations of these CysLTs ([@B68]). These ligands regulate human airway contractions upon binding to the CysLT receptors ([@B76]; [@B110]; [@B32]; [@B57]).

Polymorphic variability is found within many of the genes involved with the synthesis and signaling pathways of CysLTs. The influence of these variations to CysLT biosynthesis enzyme activity, CysLT signaling and asthma severity will be reviewed below. It is important, however, to distinguish between the effect of functional variants of risk alleles for atopy or asthma from pharmacogenetic variants that primarily influence the absorption or response to LTMs. Pharmacogenetic variants which also confer susceptibility to disease will be discussed in Section "Cysteinyl Leukotriene Receptor Polymorphisms."

Many loci implicated in LTM pharmacogenetics, however, encode genes that are independent of CysLT-related pathways. For example, rs12422149, a common c.935G \> A polymorphism in the Solute Carrier organic anion transporting polypeptide (OATP) 2B1 (SLCO2B1) was associated with absorption of and response to montelukast in humans. In particular, *in vitro* studies have shown that citrus juice may reduce the permeability of montelukast. Moreover, pharmacokinetic studies of montelukast co-ingested with citrus juice suggest that co-ingestion resulted in genotype specific alterations in absorption. For example, A/G heterozygotes were demonstrated to have reduced absorption relative to G/G homozygotes, independent of treatment or combined treatments ([@B82]).

Increasingly, loci of pharmacogenetics significance have been identified by GWAS. These data underscore the fact that many loci that alter the efficacy of LTMs pharmaceuticals are not directly part of the CysLT pathway. Seminal studies by Dahlin et al. examined patient response to montelukast and the 5-LO inhibitor zileuton, over 8 weeks and ([@B23]) and 12 weeks ([@B22]), respectively, using DNA and phenotypic information from 526 and 217 people enrolled in placebo-controlled trials. This group based their initial analysis on the genome-wide genotype and phenotypic data from American Lung Association's Asthma Clinical Research Center (ALA-ACRC) cohorts. These results showed that while rs6475448 \[located in the myeloid/lymphoid or mixed-lineage leukemia (*MLLT3*) gene\] was associated with improved montelukast response over an 8-week treatment period ([@B23]), rs12436663 \[located in the Mitochondrial Ribonuclease P Protein 3 Precursor (*MRPP3*) gene, encoding a protein critical to the cleavage of tRNA molecules\], was associated with worsened zileuton response over a 12-week period ([@B22]). In both studies, the change in Forced Expiratory Volume (ΔFEV) from baseline in response to drug was used as a measure of treatment response ([@B23], [@B22]). Furthermore, the gene-environment (G × E) GWAS model evaluated in the 12-week study identified an association between rs517020 (located in the glycosyltransferase 1 domain containing 1 (*GLT1D1*) gene) with worsening responses to both montelukast and zileuton ([@B22]). These findings implicate loci in LTM response that, by contrast with leukotriene candidate genes, are not intuitively related to LTM therapeutic responsiveness ([@B23], [@B22]).

Next, we will review the polymorphisms in the genes encoding portions of the CysLT pathway implicated in asthma pathogenesis and treatment (**Figure [1](#F1){ref-type="fig"}**) before discussing the receptor polymorphisms *per se*.

Leukotriene Synthesis
=====================

Leukotrienes are fatty acid-derived mediators which are divided in two main biologically active subgroups, LTB4 and the cysteine-conjugated leukotrienes (LTC4, LTD4, and LTE4). The arachidonate 5-lipoxygenase (ALOX5) is required for the synthesis of the unstable epoxide precursor LTA4 (**Figure [1](#F1){ref-type="fig"}**), on which acts the leukotriene A4 hydrolase (LTA4H) to originate the proinflammatory chemoattractant LTB4 or the leukotriene C4 synthase (LTC4S) to conjugate the tripeptide glutathione and form LTC4; LTD4 and LTE4 are then formed by subsequent removal of the terminal amino acid of the tripeptide. The genes which encode for the leukotriene synthesis enzymes all have polymorphisms that have been investigated in asthma endophenotypes ([@B18]; [@B111]).

ALOX5 Polymorphism
------------------

The polymorphic region of the ALOX5 gene contains a functionally important variable number tandem repeat (VNTR) sequence (rs59439148). The VNTR of the SP1-binding motif of the ALOX5 promoter ([@B42]) is likely to determine the expression levels of ALOX5 ([@B42]; [@B101]). An early study found that patients with no wild type (WT) allele at the ALOX5 promoter locus have a diminished response to treatment with the 5-LO inhibitor, ABT-761, which targets ALOX5 ([@B27]). Though this polymorphism may not predict asthma risk ([@B98]), it may be a significant determinant of the leukotriene burden associated with bronchoconstriction ([@B40]; [@B25]). More recently, ALOX5 polymorphisms have been associated with increased cysteinyl leukotriene production as well as reduced lung function in children with poorly controlled asthma ([@B81]). In this study, 270 children, 6- to 17-years old, with poorly controlled asthma were enrolled in a 6-month clinical trial. A smaller cohort of 137 patients was examined in order to test the association of the ALOX5 promoter with asthma outcomes using both additive and recessive genetic models. Mougey et al. reported that between 14.8% (40/270) and 28% (38/135) of African Americans were homozygous for variant alleles of rs59439148. These results suggest that the ALOX5 promoter contributes to increased urinary LTE4 levels, reduced lung function and potentially worse asthma control. ALOX5 promoter variants may, therefore, be a risk factor for worse asthma outcomes.

The ALOX5 variants that confer susceptibility to asthma, therefore, may be of pharmacogenetic significance if an inadequate quantity of ALOX5 protein is available as a drug target ([@B65]; [@B116]; [@B112]). Evidence that g.20C \> T (rs4987105) and g.213411G \> A (rs4986832) are associated with improved forced expiratory volume (FEV1) in response to montelukast, suggests the clinical relevance of the ALOX5 polymorphisms ([@B56]). These studies suggest that the 15% or so of individuals who carry these SNPs may have a heightened response to montelukast that reflects their endogenously excessive levels of CysLTs.

LTC4S Polymorphism
------------------

There is evidence that the gene encoding LTC4S, the enzyme that adducts glutathione at the C-6 position of the arachidonic acid backbone ([@B61]), is also polymorphic. The promoter of the LTC4S gene contains a -444A \> C SNP which is transcriptionally active. However, the activity of this polymorphic promoter is reported to cause alterations in CysLT production which are associated with severe asthma ([@B95]; [@B52]). This relationship has been confirmed by meta-analysis ([@B137]).

The variant may be of pharmacogenetic significance. Subjects who were homozygous for the WT LTC4S -444A allele had a lower response to the CYSLTR1 antagonist zafirlukast, compared with CC or CA genotypes ([@B95]). Two recent studies report the profound physiological and functional significance of this polymorphism. The first study found that, compared with corn oil, a combination of borage and echium seed oils may improve airflow obstruction in mild to moderate asthmatics who carry the variant allele in the LTC4S gene (A-444C; [@B50]). The second group that investigated urinary leukotrienes reported that leukotriene E4 levels may be higher in patients with the LTC4 synthase -444 A/C polymorphism ([@B45]).

The efficacy of LTMs such as Montelukast are influenced my many polymorphisms in addition to -444A/C *LTC4* polymorphisms. For example, the -441T/C polymorphism of the prostaglandin D2 receptor (*PTGDR*) gene is associated with treatment responsiveness to montelukast. In particular, when LTA release was examined by exercise challenge in 100 asthmatic children prescribed 5 mg/kg Montelukast, it was found that minor alleles of the *PTGDR* -441T/C and *LTC4S* -444A/C polymorphisms were associated with eosinophil count in atopic asthmatic children. While the *LTC4S* -444A/C and *PTGDR* -441T/C were not associated with the susceptibility for asthma, there was a significant association between responsiveness to montelukast and the *PTGDR* polymorphism. These pharmacogenetic data suggest that therapies that target the PTGDR may be useful for modulating the responsiveness to LTRAs ([@B48]).

These observations suggest that the genes encoding the CysLT pathway (**Figure [1](#F1){ref-type="fig"}**), may contribute additively or synergistically to altered drug responses or asthma endophenotypes. This phenomenon was previously suggested by [@B86]. This group reported that the *LTC4S* -444A \> C \[c.-444A \> C\] gene polymorphism, in conjunction with the rare c.-819T \> G, c.2078C \> T or c.2534A \> G alleles of the *CYSLTR1* gene, was associated with aspirin intolerant asthma ([@B86]). [@B3] initially showed that SNPs of the *ALOX5, CYSLTR1*, and *ALOX5* genes were found to be associated with allergic rhinosinusitis. However, the association was diminished upon correction for multiple testing. This may have resulted because the study lacked the power to detect polymorphisms conferring a relative risk of 2.0 or less to the phenotype: reflecting the fact that individual risk factors for complex disease can be quite small ([@B3]). However, while an association of the *LTC4S* -1072G/A, rs377694, and rs730012A/C haplotype with asthma was reported, no evidence of an interaction with the *CYSLTR1* gene was identified ([@B58]).

Study of genetic variability in the genes conferring response to LTMs, including those encoding the CysLT pathway (**Figure [1](#F1){ref-type="fig"}**), therefore, should be subjected to GWAS analysis since this method is well-suited to assessing the addictive or multiplicative contribution of genes complex traits.

CYSTEINYL Leukotriene Receptor Polymorphisms
============================================

There are two distinct genes which encode the two CysLT receptors: the cysteinyl leukotriene 1 (*CYSLTR1*) and 2 (*CYSLTR2*) receptors genes. These two receptor proteins exhibit variable tissue expression, however, both are expressed in lung macrophages and in airway smooth muscle (ASM; [@B76]; [@B67]; [@B38]; [@B110]; [@B32]; [@B79]). Knock-out mouse studies have given insight into the pathobiology mediated by the CysLTs ([@B47]). *CYSLTR2* was revealed to have a major role in chronic inflammation associated with fibrosis ([@B9]). By contrast, *CYSLTR1* was found to be associated with acute constriction of smooth muscle and anti-inflammatory counteraction of chronic injury ([@B10]). Biochemical studies have also shown that these two receptors are functionally distinct. Although, CYSLTR1 has its highest affinity for LTD4 ([@B67]; [@B132]), CYSLTR2 binds LTC4 and LTD4 with equal affinity ([@B38]; [@B69]); a phenomenon that may define the specificity of the acute and chronic activity of the CysLTs.

As with other GPCR genes, variants of the cysteinyl leukotriene receptors (CysLT) include single nucleotide polymorphisms and insertion or deletions that alter GPCR expression or function ([@B5]). Early evidence of the possible significance of CysLT receptor variability was observed in mice: in which the *CYSLTR1* transcript has been shown to undergo alternative splicing that alters the function of the protein ([@B69]). From 2001 to the present, a number of groups have been investigating the contribution of variability of the two CysLT receptors to atopic asthma and response to pharmacological interventions. Selected CysLT receptor polymorphisms are presented in **Tables [2](#T2){ref-type="table"}** and **[3](#T3){ref-type="table"}**.

Human polymorphisms, including coding variants as well as has functional promotor haplotypes that either increase or decrease the expression of either receptor are presented in **Tables [2](#T2){ref-type="table"}** and **[3](#T3){ref-type="table"}**. The epidemiology and *in vitro* studies discussed below suggest that functional receptor variants are associated with asthma endophenotypes and altered pharmacological response once environmental factors such as smoking were controlled for ([@B120]). The disturbances include the alteration of: ligand binding; G-protein coupling; dimerization; desensitization; receptor trafficking to the cell surface as well as receptor mRNA expression ([@B91]; [@B120]).

Early studies of the effect of amino acid substitutions in the CYSLTR1 and CYSLTR2 receptor genes in atopic asthma were based on a personalized medicine hypothesis ([@B117], [@B125], [@B121]; [@B18]). The LTM class of drugs has been found to be ineffective in greater than 20% of patients ([@B83]). We originally hypothesized that genetic polymorphisms influenced the efficacy of drugs that act at the CYSLTR1 receptor, such as the high-affinity antagonist ligands (e.g., montelukast, pranlukast, zafirlukast; [@B93]; [@B34]; [@B109]; [@B84]). Further, we proposed that even though the CYSLTR2 receptor is not a current drug target, knowledge of the polymorphisms of this potential drug target maybe clinically valuable to refractory patients in the future.

We discuss these findings in the context of the body of cysteinyl leukotriene receptor pharmacogenetics that has since been established. Selected CYSLTR1 and CYSLTR2 polymorphisms are presented in **Tables [2](#T2){ref-type="table"}** and **[3](#T3){ref-type="table"}**.

Cysteinyl Leukotriene 2 Receptor Polymorphisms
----------------------------------------------

Four independent groups ([@B122], [@B118]) have identified significant associations between the CYSLTR2 gene loci and atopy ([@B33]; [@B89]; [@B86]; [@B118]). The amino acid alignment (**Figure [2](#F2){ref-type="fig"}**) shows the location of CYSLTR2 variant with respect to the transmembrane (TM) domains. The CYSLTR2 receptor is shown schematically in **Figure [3](#F3){ref-type="fig"}**.

![**Alignment of the protein structure of the cysteinyl leukotriene 1 (CYSLTR1) and 2 (CYSLTR2) receptors in relation to rhodopsin.** The amino acids conserved between these family A receptors are shown. The consensus is greater than 50%. These data formed the basis of the model predicting the CYSLTR1 and CYSLTR2 transmembrane domains (helices 1--7), the four β-sheets, and the putative cysteinyl leukotriene-binding domain. The amino acid variants that are associated with atopy or asthma, the G300S CYSLTR1variant, and the M201V CYSLTR2 variant are each boxed and noted with arrows (adapted from [@B120]).](fphar-07-00299-g002){#F2}

![**Structure of the cysteinyl leukotriene 2 (CYSLTR2) receptor and variants.** The positions of the transmembrane (TM)-spanning domains of the CysLT receptor, the putative binding pocket, and the Met201Val amino acid substitution are shown in relation to the cutaway plasma membrane.](fphar-07-00299-g003){#F3}

The 610 A \> G variant which encodes the Met201Val CYSLTR2 receptor variant was originally identified in the Tristan da Cunha population has also been reported by [@B89]. A less remarkable Ser236Leu variant, which was originally identified in the Tristan population ([@B122]), may be present in as many as 10% of persons of African descent according to the Exome Aggregation Consortium, ExAC^[1](#fn01){ref-type="fn"}^. Though the Ser236Leu variant has not been examined in asthmatics of African origin, it has been seen compounded with Met201Val. This may be important for Tristanian asthmatics identified to be compound heterozygous for the Met201Val and Ser236Leu variants of CYSLTR2.

The Met201Val variant that was found to be associated with atopic asthma on Tristan da Cunha (**Table [3](#T3){ref-type="table"}**) has subsequently been reported to have frequency of between 2.6% in the general population according to the Exome Aggregation Consortium (ExAc)^1^. The essentially inactivating character of the Met201Val the polymorphism ([@B122]), to be discussed in below, has been confirmed by the group of [@B89] Their data show that Met201Val is associated with asthma phenotypes in a large population genetics study. Definitive studies using SNPs that saturate *CYSLTR2* may be necessary before these findings are placed in context, however, since association studies with non-coding SNPs or haplotypes built from only a few SNPs ([@B49]; [@B58]) are unlikely to be definitive.

Cysteinyl Leukotriene 1 Receptor Variants
-----------------------------------------

The presence of SNPs in both the *CYSLTR1* and *CYSLTR2* genes may increase the risk for atopic asthma (**Tables [2](#T2){ref-type="table"}** and **[3](#T3){ref-type="table"}**). Since the CYSLTR1is the target for anti-asthma drugs such as montelukast, the *CYSLTR1* SNPs may provide an opportunity to examine the amino acid residues necessary to the structure-activity relationships that define drug action. The *CYSLTR1* gene, located at Xq13-21.1, has been examined in atopic asthma (**Table [2](#T2){ref-type="table"}**). *CYSLTR1* variants, such as the 927 T \> C variant (rs320995), have been associated with asthma ([@B41]) in out-bred populations. While this SNP was also noted in the Tristan da Cunha population ([@B118]), it has not been replicated in all studies of atopic asthma ([@B45]). A nucleotide substitution at 898G \> A resulting, *in vitro*, in a functional Gly300Ser substitution ([@B119]) is discussed below.

Taken together, many studies suggest that transcriptionally active *CYSLTR1* variants influence the onset and severity of asthma associated endophenotypes such as atopy ([@B104]). The significance of *CYSLTR1* variants can be interpreted in the context of a large study of asthmatics born in Great Britain during 1958. This study, however, did not identify coding variants associated with atopy or asthma ([@B29]). Among those variants examined *in vitro*, only the 206Ser variant has been found by the Exome Aggregation Consortium^1^. Our ongoing GWAS study of Tristan da Cunha will ultimately resolve the questions raised by the pioneering work we undertook in this population.

Co-inheritance of CYSLTR1 and CYSLTR2 Variants
----------------------------------------------

We can hypothesize that epistasis involving inheritance of variants of both receptors contributes to the phenotype. The putative co-inheritance of *CYSLTR1* and *CYSLTR2* variants suggest a mode of asthma inheritance that is the result of epistasis. Proof of principal may be found in data showing that variants of two genes encoding other GPCR pathway proteins appear to be implicated in asthma pathogenesis. For example, it is likely that an interaction between variant forms of *NPSR1* with variants of the retinoid receptor-related orphan receptor alpha (*RORA*) nuclear repressor gene may contribute to a variety of asthma phenotypes ([@B1]). Similarly, the contribution of *CYSLTR1* and *CYSLTR2* alleles may contribute additively or synergistically to asthma in association with other risk alleles and environmental factors.

Pharmacology of CYSLTR1 and CYSLTR2 Receptor Variants
=====================================================

The associations of the *CYSLTR1* and *CYSLTR2* genes with atopy and asthma provided the rationale for studying the functional consequences of these variants with respect to agonist and their possible contribution to the atopy phenotype ([@B122], [@B119], [@B118]). By contrast, a putative high affinity LTE4 receptor ([@B46]), GPR99 (also known as an oxoglutarate receptor) may not be involved since the actions of LTD~4~ can account for the phenotype at the cognate CYSLTR1 and CYSLTR2 receptors. The CysLT receptor CYSLTR2 variants are discussed in the context of their potential to influence LTM response.

Functional Variants of CYSLTR2
------------------------------

The 601 A \> G variant that is associated with atopic asthma in both the Tristan da Cunha ([@B122]) and European populations ([@B89]) encodes the Met201Val variant of transmembrane domain five (TMD5; **Figure [3](#F3){ref-type="fig"}**). GPCR models suggest this variant creates a mildly deleterious hypomorphic protein ([@B15]; [@B51]; [@B14]; [@B130]; [@B90]; [@B120]). Our work has recently confirmed the variant to be hypomorphic ([@B13]). The CYSLTR2 inactivating mutation results in reduced ligand binding, Ca^2+^ flux (**Figures [4D](#F4){ref-type="fig"}** and **[5B](#F5){ref-type="fig"}**) and inositol phosphate (IP) generation (**Figure [6](#F6){ref-type="fig"}**; [@B122]; [@B89]; [@B13]).

![**Radioligand binding studies of LTC~4~ or LTD~4~ with CYSLTR2 WT or CYSLTR2 Met201Val cells. (A,B)** Saturation binding isotherms for \[^3^H\]LTC~4~ to CYSLTR2 WT **(A)** or CYSLTR2 Met201Val **(B)**. Radioligand binding assay was performed with increasing amounts of \[^3^H\]LTC~4~ (0.1--12 nM) in the presence or absence of unlabeled ligand. **(C,D)** Saturation binding isotherms for \[^3^H\]LTD~4~ to CYSLTR2 WT **(C)** or CYSLTR2 Met201Val **(D)**. Radioligand binding assay was performed with increasing amounts of \[^3^H\]LTD~4~ (0.1--15 nM) in the presence or absence of unlabeled ligand. The calculated specific binding was analyzed by non-linear transformation using Prism (Graph Pad Software, Inc.) to generate *K*~d~ and *B*~max~ values. Saturation curves are representative of four independent experiments. Insets: Scatchard representation of the specific binding isotherm (adapted from [@B13]).](fphar-07-00299-g004){#F4}

![**Summary of the *in vitro* effects of Gly300Ser cysteinyl leukotriene 1 (CYSLTR1) receptor and Met201Val on CYSLTR2 receptor signaling compared with wild type (WT). (A)** Cysteinyl leukotriene D (LTD) concentration-response curve for CysLT receptors in transfected cells. Inositol triphosphate (InsP) generation assay of the variants and WT forms of the CYSLTR1 receptor. both 300Ser and 206Ser variants' EC50 were significantly different from WT. The concentrations of LTD required to produce the InsP effect were much higher than those used in the \[Ca^2+^\] assay shown in **(B)**, in which calcium flux was assayed for the variants and WT and variant forms of the CYSLTR1 receptor challenged with LTD. The resulting changes in intracellular calcium concentrations were measured as fluorescence maximum. For LTD4, the Met201Val variant (○) had a significantly greater EC50 compared to WT (■), while the Ser236Leu(Δ) and Ala293Gly/Arg316Lys (^®^) variants were not different. However, the Ala293Gly/Arg316Lys variant showed decreased efficacy (V; adapted from [@B120]).](fphar-07-00299-g005){#F5}

![**Effect of CysLTs on IP production by CYSLTR2 WT (black bars) or CYSLTR2 Met201Val (gray bars) cells.** Cells were labeled with \[^3^H\]myo-inositol for 16 h, and then stimulated for 45 min with EtOH and LTC~4~ **(A)** or LTD~4~ **(B)** at the indicated concentrations before measurement of radioactivity. Results are presented as cpm of inositol phosphate production. Data are expressed as mean ± SE of 15 **(A)** or 9 **(B)** independent experiments. Lane C, control using EtOH (100 nM). ^∗∗∗^*p* \< 0.001, using two-way ANOVA with Bonferroni post-tests (adapted from [@B13]).](fphar-07-00299-g006){#F6}

In general, the effects of Met201Val were more pronounced with respect to LTD~4~ compared with LTC~4~. This effect is compounded by deficits in ligand binding that were again more significant for LTD~4~ than LTC~4~ (**Figure [4](#F4){ref-type="fig"}**). The fact that LTD~4~ release is more commonly associated with asthma severity, may explain why this variant is clinically relevant. The fact that the CYSLTR2 variant is both relatively common and associated with asthma in out-bred populations suggests that the variant is of relevance to the general population.

Functional Variants of CYSLTR1
------------------------------

Since the CYSLTR1 Gly300Ser variant has not been reported in the general population, our functional analysis of the Gly300Ser variant will be especially informative if the CYSLTR1 gene is implicated in disease pathogenesis. Our *in vitro* study of the Gly300Ser variant (**Figures [7](#F7){ref-type="fig"}** and **[8](#F8){ref-type="fig"}**; [@B134]) provided among the first structural insights into CysLT receptors using site directed mutagenesis. This represents a significant advance in understanding the relatively under-studied GPCR receptors for the cysteinyl leukotrienes.

![**Binding of LTD4 to the CYSLTR1-WT receptor and its variants in transiently transfected HEK293 cells.** Forty-eight hours post-transfection, 3H-LTD4 was added to the cells for 1 h, in the presence or absence of non-radioactive LTD4. Following several washes, the radioactivity was measured in a beta-counter (*n* = 3). Specific binding was calculated by subtracting the non-specific binding (in presence of competition from radioactive LTD4) from the total binding measured ([@B134]).](fphar-07-00299-g007){#F7}

![**Inositol phosphate production in CYSLTR1-transfected cells.** Forty-eight hours post-transfection, cells were stimulated for 30 min with LTD4 or LTC4 at 0.01--100 nM. IP-1 production was measured using an antibody against IP-1 and a fluorescent FRET IP-1 conjugate competitor. **(A)** IP-1 production by CYSLTR1-transfected HEK-293 cells in response to LTD4 **(B)** and to LTC4. Two-way ANOVA analysis; *n* = 6; ^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001 (adapted from [@B134]).](fphar-07-00299-g008){#F8}

When the engineered Gly300Ser variant receptor was expressed it in COS-7 cells, the variant was more sensitive to the LTD~4~ agonist (**Figures [7](#F7){ref-type="fig"}** and **[8](#F8){ref-type="fig"}**). Binding properties of the variant (measured by B~max~ and K~d~) indicates that the CYSLTR1 variant has higher affinity for ligand than the WT (**Figure [7](#F7){ref-type="fig"}**) by comparison with the CYSLTR2 polymorphism that has less affinity for ligand than the WT (**Figure [4](#F4){ref-type="fig"}**). By contrast, the CYSLTR1 206Ser variant, originally identified in the Tristan da Cunha population, and later found at low frequencies in atopics, asthmatics and control subjects throughout the world, was not found to be functional ([@B119]; [@B134]).

In fact, while ligand binding (**Figure [7](#F7){ref-type="fig"}**), IP generation (**Figure [8](#F8){ref-type="fig"}**) and Ca^2+^ flux (**Figure [5A](#F5){ref-type="fig"}**) was reduced compared to CYSLTR1 WT, the expression of the CYSLTR1 Gly300Ser variant receptors (**Figure [9](#F9){ref-type="fig"}**) and their desensitization in response to agonist was found to be normal ([@B119]). These data suggest that CYSLTR1 CYSLTR1 antagonists, such as montelukast, may correct a putative elevation in CYSLTR1 signaling in atopic asthma.

![**Confocal microscopy imaging of cysteinyl-leukotriene 1 (CYSLTR1) WT and variant receptors in transiently transfected cells.** Cells were fixed and immunofluorescently stained with anti-CYSLTR1R antibody (green) followed by Alexa 488 goat anti-rabbit antibody (red) as described under Methods section. Superimposed images of immunoreactivity of **(a)** WT CYSLTR1 receptor, **(b)** Gly300Ser CYSLTR1 receptor variant or **(c)** Ile206Ser CYSLTR1 receptor variant, in basal condition. One representative experiment is shown (adapted from [@B119]).](fphar-07-00299-g009){#F9}

The relative location of variants of the receptors is shown in an alignment of each CysLT receptor (**Figure [2](#F2){ref-type="fig"}**) that was constructed with respect to the transmembrane-spanning and the putative binding pocket of the receptors. The data suggests that the putative CysLT binding site is partially determined by the integrity of the transmembrane domains. The abnormal but opposite pharmacology of variants of the receptors, causing increased potency of LTD~4~ at the Gly300Ser CYSLTR1 receptor variant (located in the intracellular portion of TMD7) and decreased potency of LTD~4~ at the Met201Val CYSLTR2 receptor variant (located in the extracellular portion of TMD5) contributes important *in vitro* data on the structural significance of the specific amino acid residues in these GPCRs.

Putative Interaction between the CYSLTR1 and CYSLTR2 Receptors
--------------------------------------------------------------

It has been proposed that macrophages and eosinophils attenuate the strength of CysLT-mediated signaling by limiting the formation of CYSLTR1 receptor homodimers and/or controlling their surface expression. With respect to MAP Kinase signals, it seems possible that WT CYSLTR2 receptors interact with WT CYSLTR1 receptors to inhibit functional responses of WT CYSLTR1 receptors. In mast cells, ligand activation of the WT CYSLTR2 receptor results in reduced signaling from ligand activated CYSLTR1 WT receptors. Although, the CYSLTR1 and CYSLTR2 receptor interaction is best modeled with respect to mitogenic signals ([@B44]), it is possible that more rapid processes such as IP generation or calcium flux may be analogous. We hypothesize that a CYSLTR1/CYSLTR2 "counterbalance" may regulate CysLT-dependent functions in immune and inflammatory responses. This balance may be disrupted by the Met201Val variant of CYSLTR2 if the LTD~4~ dependent signal is necessary to balance the LTD4 ligand-dependent CYSLTR1 signal. This effect may be amplified in people who also carry a *CYSLTR1* variant.

The CYSLTR2 receptor may be important to the pharmacology of CYSLTR1 pharmaceuticals if, like many GPCRs, these receptors form functional heterodimers with unique pharmacological properties. Co-expression of variant receptors may alter CysLT signaling. While evidence for a functional interaction between CYSLTR1 and CYSLTR2 receptors in mast cells seems likely ([@B44]), the functional consequence of putative heterodimers, or other functional interactions formed between variants, remains to be fully demonstrated. The fact that deletion of either the CYSLTR1 or CYSLTR2 receptors totally eliminates CysLT-mediated cutaneous edema ([@B67]), however, suggests that a CYSLTR1/CYSLTR2 interaction may regulate some responses to CysLT mediators. It may be possible to test the hypothesis that CYSLTR2 negatively regulates CYSLTR1 signaling by examining the signaling consequences of co-expressing CYSLTR1 variants with the 201Val CYSLTR2 variant.

Conclusion
==========

Central to this narrative is a discussion of how variability in the genes encoding the proteins essential for CysLT signaling may influence risk for inflammation that is associated with asthma, cognizant of the fact that variability these genes may also increase susceptibility to asthma independent of their potential LTM pharmacogenetic relevance. Asthma susceptibility loci, which confer risk for the complex respiratory traits that lead to asthma, and pharmacogenetic loci, which confer the traits that define the responsiveness of an individual to pharmaceutical therapy, are presented in the context of the linkage analysis, candidate gene studies and/or GWAS approaches used to identify them. In most cases, these loci can be modeled as independent complex traits with both genetic and environmental (GXE) contributions. Therefore, we review the relative contribution of genes in the CysLT pathway to both the etiology of asthma itself and a person's responsiveness to LTM drugs.

Common genetic variants (e.g., SNPs) typically contribute effects of as little as 1% to a complex phenotype described in a given population. As a result, GWAS can be used to confirm the significance of the cysteinyl leukotriene gene variants to atopic asthma on Tristan da Cunha. While it is possible that affected Tristanians may inherit a variety of other genetic risk factors for atopy and/or asthma, including potential *ETS-2* and *ETS-3* variability ([@B6]; [@B100]; [@B133]), we present evidence that suggests that the *CYSLTR2* 601 A \> G variant is associated with atopic asthma. The contribution of other known atopy variants, such as those in the *DENND1B* gene, located on chromosome 1q31 ([@B102]) and the *ORMDL3* gene, located on chromosome 17q12 ([@B80]) to the asthma phenotype is also possible. Like other asthma susceptibility loci, the *CYSLTR2* 601 A \> G variant has been shown to contribute to asthma in large out-bred populations ([@B89]).

While the *CYSLTR2* variant was originally identified in 13% of the Tristan da Cunha population ([@B122]) it is only present in approximately 2.6% in the European population. In both instances, the variant has been associated with atopic asthma ([@B122]; [@B89]). A large study of *CYSLTR1* variants in asthmatics born in Great Britain during 1958 did not identify the 898 G \> A variant ([@B29]) nor is it found in over 60,000 exomes by the Exome Aggregation Consortium^1^. The 898 G \> A *CYSLTR1* is, however, among the best studied coding variants of a receptor for any LTM drug.

By contrast with asthma susceptibility loci, in most cases the pharmacogenetic determinants of drug response represent a distinct category of risk loci that may not influence disease onset directly. For example, the pharmacogenetic variability that influences LTM response can be attributable to genes that are both integral ([@B48]; [@B81]; **Figure [1](#F1){ref-type="fig"}**), or lie outside ([@B23], [@B22]) CysLT signaling pathways. In this context, CysLT receptor variants have provided insight into the role of GPCR variants as genetic risk factors for disease, altered drug response, or ADRs (see **Table [1](#T1){ref-type="table"}**) and may represent reagents necessary for refined LTM drug discovery and/or personalized medical interventions ([@B107]). The significance of the CysLT receptor variants to both the development of asthma and LTM response, however, is best evaluated in the context of other polymorphisms that influence the phenotype. For example, the enzymes involved in the formation of the leukotrienes (**Figure [1](#F1){ref-type="fig"}**) often result in variable production of the CysLTs (LTC4, LTD4, and LTE4) and LTB4. The many examples discussed include, the VNTR sequences located in the Sp1-binding motif within the promotor region of the ALOX5 gene that are associated with both LTM response, leukotriene burden and bronchoconstriction ([@B25]), and the 444A \> C SNP polymorphism in the LTC4S gene that is associated with severe asthma, leukotriene burden and altered response to the CYSLTR1 LTMs ([@B95]; [@B45]; [@B50]). Genetic variability in CysLT pathway may contribute additively or synergistically to altered drug responses.

Since very large GWAS studies are needed to detect polymorphisms conferring a relative risk of 2.0 or less to the phenotype ([@B3]), results suggesting that *CTSLT1R* variants may interact with other polymorphic variants can be difficult to replicate ([@B58]). This may reflect the fact that LTM targets can be quite diverse. For example, the fact that *PTGDR* polymorphism has been significantly associated with responsiveness to montelukast may confound earlier studies of LTM pharmacogenetics. Indeed, LTM therapies may be developed that selectively target the PTGDR since this receptor may be a useful way to modulate responsiveness to LTRA ([@B48]).

Many genes that are associated with altered efficacy of LTMs pharmaceuticals, however, are not directly part of the CysLT pathway. For example, variation in the SLCO2B1 gene has associated with altered absorption of montelukast administered in the presence of citrus. These data suggest that genetic factors influence pharmacokinestics of LTM response ([@B82]).

GWAS studies of LTM response in people enrolled in placebo-controlled trials have also been undertaken. [@B23], [@B22]) examined LTM response using DNA and phenotypic information from placebo-controlled trials from the American Lung Association's Asthma Clinical Research Center (ALA-ACRC) cohorts. SNPs that both favored \[rs6475448, located in the myeloid/lymphoid or mixed-lineage leukemia (MLLT3) gene; [@B23]\], or worsened \[rs12436663, located in the Mitochondrial Ribonuclease P Protein 3 Precursor (MRPP3) gene\], rs517020 \[located in the glycosyltransferase 1 domain containing 1 (GLT1D1) gene\] LTM response have been identified ([@B22]). These findings implicate loci in LTM response that, by contrast with CysLT receptor genes or the biosynthesis genes (**Figure [1](#F1){ref-type="fig"}**), are not intuitively related to LTM therapeutic responsiveness ([@B23], [@B22]).

As a result, it is necessary that a GWAS approach is used to confirm the significance of the putative contribution of cysteinyl leukotriene gene variants to asthma and/or drug response in the context of other asthma susceptibility genes and genes that influence LTM pharmacogenetics. This strategy might we reveal novel genotype--phenotype correlations; as we did for the melanocortin 1 receptor (MC1R) variants ([@B8]).

With respect to Tristan da Cunha, this analysis is likely to identify variety of other genetic risk factors for atopic asthma and/or LTM drug response. These include loci associated with asthma in other populations such as the *DENND1B* gene, located on chromosome 1q31 ([@B102]). Exclusion of the *ORMDL3* gene, located on chromosome 17q12 ([@B80]), may also be possible. In addition, loci already implicated in the Tristan phenotype such as *ETS-2* and *ETS-3* ([@B6]; [@B100]; [@B133]) and the better documented *CYSLTR2*, can be evaluated in the context of those loci, such as *CYSLTR1*, that may have pharmacogenetic significance.
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